BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Magliozzi R, Marastoni D, Calabrese M. The BAFF / APRIL system as therapeutic target in multiple sclerosis. Expert Opin Ther Targets 2020;24:1135-45. [PMID: 32900236 DOI: 10.1080/14728222.2020.1821647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Brummer T, Ruck T, Meuth SG, Zipp F, Bittner S. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Ther Adv Neurol Disord 2021;14:17562864211035542. [PMID: 34457039 DOI: 10.1177/17562864211035542] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Smets I, Prezzemolo T, Imbrechts M, Mallants K, Mitera T, Humblet-Baron S, Dubois B, Matthys P, Liston A, Goris A. Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis. Front Immunol 2021;12:676619. [PMID: 34122439 DOI: 10.3389/fimmu.2021.676619] [Reference Citation Analysis]
3 Quartuccio L, De Marchi G, Longhino S, Manfrè V, Rizzo MT, Gandolfo S, Tommasini A, De Vita S, Fox R. Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine. Front Immunol 2021;12:703780. [PMID: 34322134 DOI: 10.3389/fimmu.2021.703780] [Reference Citation Analysis]